Traduction de «medicines that have been identified as nonconforming » (Néerlandais → Français) :

Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.
Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.

As a result of this lack of availability, the care provided is often restricted to a vague nosographic diagnosis and a decision to admit the patients in question to the psychiatric department (the cost of which might have been saved) or to send them to a consultation. Attention is only paid to the “identified patient” rather than to devising a real therapeutic follow-up that involves the complete system.
Par ce manque de disponibilité, l’intervention se limite souvent à un vague diagnostic nosographique et à une décision d’hospitalisation en service de psychiatrie (dont on aurait pu faire l’économie) ou d’envoi en consultation, portant leur attention sur le seul « patient désigné » plutôt que d’amorcer un véritable suivi thérapeutique avec l’ensemble du système. ♦ une méconnaissance des ressources du réseau psychosocial: « Travailler avec

Also supporting the broad expansion have been landmark data first presented in 2008, and published in early 2009 in “The New England Journal of Medicine,” that showed the significant anti-cancer benefit of Zometa in reducing the risk of cancer recurrence or death in premenopausal women with hormone-sensitive, earlystage breast cancer.
Cette large progression a été soutenue par de nouveaux résultats d’une étude pivot présentés initialement en 2008 et publiés début 2009 dans «The New England Journal of Medicine» faisant état des bénéfices anticancer importants du Zometa dans le risque de récidive ou de décès chez les femmes préménopausées atteintes d’un cancer du sein hormono-dépendant précoce.